First Manhattan’s Immunocore IMCR Stock Holding History

First Manhattan’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-613,749	Closed	-$31.9M	–	1502
2023 Q3	$31.9M	Hold	613,749	–	–	0.12%	74
2023 Q2	$36.8M	Hold	613,749	–	–	0.13%	70
2023 Q1	$30.3M	Hold	613,749	–	–	0.12%	79
2022 Q4	$35M	Sell	613,749 -182,100	-23%	-$10.2M	0.13%	72
2022 Q3	$37.4M	Hold	795,849	–	–	0.16%	63
2022 Q2	$29.7M	Sell	795,849 -12,700	-2%	-$413K	0.12%	82
2022 Q1	$24.2M	Buy	808,549 +298,693	+59%	+$7.54M	0.08%	103
2021 Q4	$17.5M	Buy	509,856 +311,857	+158%	+$11.3M	0.06%	125
2021 Q3	$7.34M	Buy	+197,999	New	+$6.68M	0.03%	181

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan's IMCR Position: Q4 2023 in Review

First Manhattan sold out of Immunocore (IMCR) in Q4 2023, closing a stake of 613,749 shares — an estimated $31.9M sold.

First Manhattan first reported a position in IMCR in Q3 2021 and held it in 9 quarters. The position peaked at $37.4M in Q3 2022. 133 funds tracked by Wall St. Rank hold IMCR as of Q4 2023.

First Manhattan reported no remaining Immunocore position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 613,749 Immunocore shares in Q4 2023, an estimated $31.9M.
First Manhattan first reported a position in Immunocore in Q3 2021 and held it in 9 quarters.
First Manhattan's Immunocore position peaked at $37.4M in Q3 2022.
133 funds tracked by Wall St. Rank held Immunocore as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.